Sonia T. Oskouei, PharmD, vice president of innovation and solution development at Premier Inc, discusses how biosimilars have impacted innovation in oncology.
Transcript
So biosimilars really have had a significant impact at innovation in general, including oncology. And so here's my perspective: I think it not only represents innovation but it also fosters innovation.
So biosimilars, the regulatory pathway, the Biologics Price Competition and Innovation Act, innovation’s in the name, was really innovative to create an expedited pathway to bring these life-saving biologic therapies to market sooner. So not only was the regulatory pathway innovative with creating the concept of extrapolation and relying on the totality of evidence to be able to do so, but also the manufacturing process for these biosimilars represent innovation.
The technology and the ability to develop these biologics have come a long way even since the originator biologics were First developed. Now the way that biosimilars have fostered innovation and continue to do so, we could see it even from the originator biologics, we could see enhanced formulations or even dosage form. So, biologics that were traditionally infused are now available [subcutaneously] to other areas that we see it fostering innovation is even in the health system setting.
Creating these biosimilar strategies and processes from a health system perspective has really catapulted the development of a true education program within health systems to ease the transition to a biosimilar or start a new biosimilar for a new patient. A lot of time that's that goes with educating nurses, physicians, pharmacists, really a multi-stakeholder approach, and really keeping the pressure patient at the forefront of it.
Being able to create the process where patients are notified, educated on what these products are, why it's okay to be switching, and the potential impact it could have on out-of-pocket costs and the finance is really important, and that's represented innovation from a process standpoint within health systems too.
Panelists Call for Consistent Education, Support to Improve Patient Comfort With Biosimilars
May 15th 2024At the Festival of Biologics USA, panelists stressed the need for patient-centered communication and education to boost comfort with biosimilars, emphasizing consistent support from health care providers despite restrictive payer policies.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.